References
- Payne D, Naruke T. Lung cancer. In: Pollock RE, Manual of clinical oncology, 7th ed. New York: Wiley; 1999:385-405
- Mountain CF. Revision in the international system for staging lung cancer. Chest 1997;111:1710-7 https://doi.org/10.1378/chest.111.6.1710
- Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, et al. Prophylactic cranial irradiation in small cell lung cancer: a systemic review of the literature with meta-analysis. BMC cancer 2001;1:5 https://doi.org/10.1186/1471-2407-1-5
- Sing T, Wu F, Brodiin O, Fasth KJ, Langstrom B, Bergstrom M. In vitro PET evaluation in lung cancer cell lines. Anticancer Res 2000;20:1375-80
- Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of F-18-FDG-PET on the primary staging of small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-20 https://doi.org/10.1007/s00259-004-1606-x
- Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small cell lung cancer preliminary experience. Am J Clin Oncol 2004;27:164-71 https://doi.org/10.1097/01.coc.0000054889.58718.6F
-
Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [
$^{18}$ F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003;30:78-84 https://doi.org/10.1007/s00259-002-0937-8 - Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci 2006;97:1291-7 https://doi.org/10.1111/j.1349-7006.2006.00341.x
- von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238: 405-22 https://doi.org/10.1148/radiol.2382041977
- Francis IR, Brown RK, Avram AM. The clinical role of CT/PET in oncology: an update. Cancer Imaging 2005;5:S68-75 https://doi.org/10.1102/1470-7330.2005.0024
- Messa C, Bettinardi V, Picchio M, Pelosi E, Landoni C, Gianolli L, Gilardi MC, et al. PET/CT in diagnostic oncology. Q J Nucl Med Mol Imaging 2004;48:66-75
- Coleman RE. Clinical PET in Oncology. Clin Positron Imaging 1998;1:15-30 https://doi.org/10.1016/S1095-0397(97)00004-6
-
Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of
$^{18}$ F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97-106 https://doi.org/10.1158/1078-0432.CCR-05-0510 - Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21 https://doi.org/10.1007/s00259-005-1919-4
- Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schafers HJ. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. Thorac Cardiovasc Surg 2004 ;128:892-9 https://doi.org/10.1016/j.jtcvs.2004.07.031
-
Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al.
$^{18}$ F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45 - Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605-13
-
Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [
$^{18}$ F] fluoromisonidazole and [$^{18}$ F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/ radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006;6:51 https://doi.org/10.1186/1471-2407-6-51 -
Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Repeat
$^{18}$ F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2007;55:165-71 https://doi.org/10.1016/j.lungcan.2006.09.028 - Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6 https://doi.org/10.1200/JCO.1999.17.10.3201
- Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107:2468-73 https://doi.org/10.1002/cncr.22268
- Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9 https://doi.org/10.1016/j.jtcvs.2004.11.007
- Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 2006;33:263-9 https://doi.org/10.1007/s00259-005-1953-2
- Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533-41 https://doi.org/10.1016/j.ejca.2005.03.026
- Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-60 https://doi.org/10.1200/JCO.2004.11.109
- Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-96 https://doi.org/10.1016/S0140-6736(05)67569-1
- Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res 2006; 15:4232-6
- Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [(18)F]-fluorodeoxy- D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88 https://doi.org/10.1200/JCO.2000.18.8.1676
- Wieder HA, Brcher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8 https://doi.org/10.1200/JCO.2004.07.122
- S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro & S. h. Kang. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-1357 https://doi.org/10.1093/annonc/mdh345
-
Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, et al. Preoperative
$^{18}$ [F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006;81:1076-81 https://doi.org/10.1016/j.athoracsur.2005.09.063 - Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33 https://doi.org/10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6
- Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, Eaton W, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989; 7:344-54 https://doi.org/10.1200/JCO.1989.7.3.344
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-74 https://doi.org/10.1200/JCO.1990.8.9.1563
- Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46: 4189-94
- Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 1991;63:986-92 https://doi.org/10.1038/bjc.1991.215